What about prescription meds with stronger evidence?

Guidelines often point to propanol, topyramate, and amatryptaline, especially amatryptal combined with CBT.

Right. The combo again.

Yeah. But each has potential side effects and contraindications you have to watch for. Propanolor can affect asthma, diabetes. Torpyram can cause drowsiness, appetite loss, interacts with birth control and is risky in pregnancy. Amatipptaline can cause weight gain, drowsiness, has cardiac risks and needs careful monitoring. And one trial questioned if the benefits of topamate and amatippline always outweigh risks in kids. Plus, the placebo effect in pediatric migraine trials is huge.

Wow. Yeah, the placebo effect is always tricky. Are there other preventive meds sometimes used?

Others sometimes considered include cyproeptadine. maybe more in younger kids but sedation and weight gain are issues. Kizotphins fluerazine lacks strong evidence. Botox has mixed trial results but some retrospective studies suggest benefit for some

meds used more in adults like blemaxine levitacetum candesartin meantine sometimes tried off label but lack strong pediatric data. Vaproic acid isn't usually recommended due to side effects. The injectable CGP antibodies available for adults but not yet approved for kids though studies are happening. maybe consider for refractory older teens. Nerve blocks are used quite often, sometimes as a bridge therapy. And again, CBT is a really important preventive strategy itself.

It really sounds like prevention requires careful individualized choices. Okay, let's quickly cover medication overuse headache, Mo. What is that exactly?

Mo or rebound headache. It's a secondary headache caused by using acute pain meds too often. Usually acetaminophen, NSAIDs, tripans, opioids. People with pre-existing migraine are more prone to it.

And the key is headache frequency plus medication. frequency.

Exactly. Diagnosis is basically headaches on 15 or more days a month for over 3 months plus regularly overusing a board of meds. That's 10 days a month for trips or guts opioids or 15 days a month for simple analesics or combos.

Sounds like a vicious cycle. What are the problems with Mo?

Big problem is headaches become more frequent often transforming episodic headache into chronic daily headache. You can get side effects from the meds themselves. Dependence, tolerance, especially with of opioids arbitrates and crucially Mo makes both preventive and acute meds less effective.

So it undermines all your treatment efforts.

Precisely. That's why education about limiting acute med use is so critical right from the start.

How do you treat Mo once it develops?

Main stay is education and gradually stopping the overuse medication. Sometimes a doctor might prescribe a long acting NSAID like neproxin for a short period during the withdrawal phase like a bridge. And often starting a proper preventive medication at the same time is key.

Okay. breaking the cycle. Finally, any overall therapeutic tips from the source for managing these headaches?

Yeah, a few key takeaways. Prognosis is generally good with early intervention, though headaches might recur later in life. Headache diaries are invaluable. Keep stressing that. Avoid triggers. Focus on lifestyle mods. Take acute meds early in an attack first 30 60 minutes.

Don't wait until it's raging.

Exactly. Use anti-imetics if nausea, vomiting are factors.

Consider preventives. If migraines are frequent, disabling, disrupting life, use that ped to score. Maybe try neutrauticals first for prevention from good sources. Aim for a goal like 83 headache days month for 61 12 months.

And if you reach that goal,

then you can think about slowly tapering off the preventive med. Some kids maintain the improvement even after stopping.

This has been incredibly thorough, a real deep dive.

Just to recap quickly, we hit the importance of diagnosis, the differences between tension type and migraine in kids, the non-drug and drug approaches for acute and preventive care, and that tricky issue of medication overuse, headache.

Absolutely. And really understanding all these pieces, you know, it empowers kids, teens, their families, helps them work better with their doctors, find the right path forward.

Totally. And given how much these headaches can really derail a young person's life, school, social life, everything. It really makes you think, doesn't it? As we learn more, as new treatments emerge, how do we make sure every kid gets access to the best, most personalized care quickly and fairly so they can just get on with being kids? meths. Definitely something to keep pushing for.

Well said.

Thanks so much for walking us through all of that really valuable information.

آلزایمر و دمانس
That little jolt of panic when you can't find your keys. Well, multiply that by the fear of genuinely losing your memories as you age. And you've hit on a very real concern for many people, Alzheimer's disease.

Absolutely. That worry, you know, the potential link people make between everyday forgetfulness and something um more serious like Alzheimer's is something we hear about a lot.

Yeah.

So, today we're going deep into this. We've got some uh accessible information sheets and also a more detailed medical review. We're going to try and unpack what they tell us about Alzheimer's and well, the broader landscape of dementia.

Okay. So, our goal here is really to cut through the noise and get to the core insights for you, the listener. We want to make clear the distinctions between, you know, normal aging and these conditions.

Explore what we currently understand about their origins, their symptoms, and look at available treatments, all while keeping it hopefully straightforward and engaging.

Exactly. Think of it as a shortcut to understanding this important topic.

Precisely. We aim to provide a clear digestible overview drawing directly from the information we have here so you can feel well more informed and maybe less overwhelmed by it all.

Okay, so let's tackle something right off the bat that I know is on many people's minds.

This worry that every forgotten name or you know misplaced item is a sign of Alzheimer's.

Yeah, that's a critical starting point, isn't it?

It really is. Our sources are quite clear. Alzheimer's disease and dementia uh in general are not considered a typical or inevitable part of growing older,

right? Not normal aging.

Exactly. While the likelihood, the risk of experiencing these conditions does increase with age, they are definitely distinct from normal age- related memory changes.

So, if it's more than just those everyday memory blips, what exactly are we talking about when we say dementia? What does that term cover?

Good question. Dementia, which you might also hear called major neurocognitive disorder or MNCD, is really an umbrella term.

An umbrella term. Okay.

Yeah. Think of it as a collection of symptoms that signal a and various brain functions. Our sources emphasize that this isn't just about memory loss.

Oh,

it can also significantly affect things like reasoning, the ability to understand language and um sound judgment. And what makes it truly impactful, what defines it really is that this decline can eventually lead to a loss of independence in managing daily life.

Right? So dementia is the broader category of that kind of cognitive decline. And where does Alzheimer's fit into that picture then? Alzheimer's disease is the most common specific cause of dementia. It's one particular way that dementia can manifest.

The most common one.

Yes. And interestingly, the medical document we have outlines several other conditions that can also lead to dementia symptoms.

Oh, like what?

Well, there's vascular dementia, which often happens after a stroke. Then there's Louisibody dementia, fronttoal dementia, and even conditions like Parkinson's disease, Huntington's disease, HIV, and uh syphilis can sometimes be associated with dementia, too.

Wow. Okay. That's a much wider range of potential causes than I think many of us typically consider. So, while Alzheimer's gets a lot of the attention,

understandably so, given it's the most common,

right? But it's definitely not the only piece of this puzzle. Let's focus specifically on Alzheimer's for a moment, though. What are some of the maybe initial signs that might suggest it's Alzheimer's?

Okay. The development of Alzheimer's symptoms is usually gradual, quite slow at first, though the speed at which they progress can differ. quite a bit from person to person.

Okay.

Often the earliest and maybe most noticeable sign is memory loss, especially um for recent information. The information sheets highlight that people might start having difficulty with tasks that were once routine.

Like what kind of tasks?

Things like managing their finances, you know, paying bills or even following a familiar recipe could become a real challenge. Communication can also be affected early on.

How so?

They might struggle to find the right words or maybe have trouble understanding even simple sentences, that kind of thing.

And how do these early symptoms tend to well evolve over time? Does it stay like that?

No. Unfortunately, it typically progresses. As Alzheimer's moves forward, we often see the emergence of disorientation and confusion. People might get lost easily, even in familiar places.

Feelings of anxiety and restlessness as well as disturbances in sleep patterns are also quite common.

And then in the later stages,

yes,

well, there there's the potential for more severe symptoms like delusions, paranoia, or even experiencing hallucinations.

That sounds very difficult.

It is. Eventually, individuals may lose the ability to recall recent events entirely, and this can progress to a complete inability to remember anything at all. Physical abilities also decline significantly,

affecting

affecting speech, mobility, and the capacity for self-care, which sadly increases their vulnerability to other problems like dehydration, malnutrition, and infections. These often become the eventual cause of death.

That gives us a sobering picture of the more advanced stages of Alzheimer's. What about dementia in general? Are the symptoms similar across the different types you mentioned?

Well, there are definitely overlapping symptoms. Yes. But the specific way dementia presents can depend on the underlying cause.

Okay, makes sense.

However, our sources point to some common symptoms that tend to develop gradually in many forms of dementia. These include increasing forgetfulness. Again, Especially for recent events and names,

right? The short-term memory issues.

Exactly. A growing difficulty in keeping track of time, becoming lost even in familiar places like their own home,

even at home. Wow.

Yes. Also, challenges with communication, asking the same questions repeatedly, needing more assistance with personal hygiene, and then in later stages, difficulties with walking, and even recognizing close family and friends.

It sounds like both Alzheimer's and other forms of dementia can just significantly disrupt a person's daily life and their or independence.

Let's shift gears slightly to what we understand about why these conditions develop. What are the known causes of Alzheimer's?

It's a complex picture. The information sheet on Alzheimer's explains that it's a degenerative brain disorder. It involves um structural and chemical changes in the brain. Specifically, there's a disruption in the communication network between nerve cells, the neurons in the brain. And this disruption unfortunately leads to the eventual death of these cells.

And do we know what causes that disruption? Well, the precise chain of events, the exact trigger is still being researched pretty heavily, but experts generally agree that it's likely a result of a combination of different factors rather than just one single cause.

A combination. Okay. And what are some of those factors that might contribute? Age is certainly one that comes to mind immediately.

Absolutely. Age is considered the single most significant risk factor for developing Alzheimer's. The vast majority of people who are diagnosed with the disease are over the age of 16. 5,

right?

But there are also genetic components. Certain genes can increase an individual susceptibility, although the information sheet does point out that these direct genetic links where a gene guarantees you'll get it, are relatively rare.

But there is a genetic link sometimes.

Yes, there is. Including one specific gene that's associated with a form of Alzheimer's that can appear much earlier in life, sometimes around the age of 40, but again, that's quite rare.

Okay. Besides age and genetics, are there other factors that might Elevate a person's risk of developing Alzheimer's.

Yes.

Research has identified several other risk factors. These include having a family history of Alzheimer's.

Okay. So, a broader family link, not just a specific gene.

Exactly. Also, experiencing a prior significant head injury, having conditions like diabetes, high blood pressure, and high cholesterol levels.

The vascular risk factors.

Precisely. As well as smoking and also having Down syndrome is associated with an increased risk.

Okay. That provides a clearer picture of who might be at higher risk. Now, what about dementia in general? Are the causes and risk factors similar to those specifically for Alzheimer's?

There's definitely overlap. The medical document indicates that the exact causes of the various other forms of dementia are also largely unknown.

Still lots of unknowns then.

Yes. However, mirroring Alzheimer's, increasing age is considered the most important risk factor across the board for dementia generally. Also, having a parent with some form of dementia can elevate an individual's risk.

So family history again,

right? And as we discussed earlier, dementia can be associated with a number of other underlying diseases. Alzheimer's itself, vascular disease leading to stroke, Louisibody dementia, Parkinson's, Huntington's, HIV, frontal dementia, and syphilis.

It seems that while the specific mechanisms might differ, there are some common threads, particularly aging, that increase the risk for both Alzheimer's and other forms of dementia. Now, this is a question I know is important. for many. Are there things we can actively do to prevent or at least reduce our risk of developing these conditions?

This is a really active area of research and um our sources offer some encouraging perspectives here regarding Alzheimer's specifically. The information sheet suggests focusing on what are termed modifiable risk factors, things we can actually change.

Modifiable risk factors. Okay. Like what

this includes things like adopting a healthy dietary pattern. Think lots of fruits, vegetables, healthy fats.

Like the Mediterranean diet people talk about

that's often cited. Yes. Also engaging in regular physical activity, keeping the mind stimulated through activities like games, puzzles, continuous learning,

keeping the brain active.

Exactly. And maintaining an active social life, staying connected with people.

Those sound like generally good recommendations for overall health. Really? Do they also apply to potentially preventing other forms of dementia?

Yes, they absolutely do. The other information sheet, the one specifically focused on dementia in seniors, rein forces these kinds of lifestyle recommendations.

Good.

It also adds the importance of stopping smoking. That's a big one. Effectively managing pre-existing conditions like diabetes, high blood pressure, depression, and high cholesterol.

So, getting those under control.

Yes. Limiting alcohol consumption, addressing hearing loss early on.

Hearing loss, that's interesting.

Yes, there's a growing link there. And also actively seeking social support and community engagement are highlighted as valuable preventative measures.

It's quite striking how many of these factors are well potentially within our power to influence. The medical document we have also digs into this area of prevention in a bit more detail, doesn't it?

It does. Yeah. The medical review highlights the significant role of these modifiable risk factors,

suggesting that potentially up to 40% for 0% of dementia cases worldwide could be attributed to these factors.

40%. That's huge. That suggests lifestyle and health and management could have a really substantial impact.

It really does. The document outlines 12 such factors specifically some we've already touched upon like lower levels of education earlier in life, social isolation, depression in later life,

okay,

midlife obesity and midlife hypertension, high blood pressure, physical inactivity, hearing impairment, diabetes, smoking, high alcohol consumption,

right?

And then a couple more, traumatic brain injury and exposure to air pollution.

Air pollution, too. Wow. Okay, so that's a comprehensive list.

The medical document also mentions specific non-farmacological preventions. strategies, right? Beyond just listing the factors.

That's right. It emphasizes the potential benefits of things like social programs aimed at reducing isolation, uh early intervention for hearing impairment, public health initiatives to reduce alcohol consumption, and smoking rates.

Makes sense.

Lifestyle modifications specifically targeting those vascular risk factors, blood pressure, cholesterol, diabetes, and inactivity.

Mhm.

And regular physical exercise. Interestingly, it notes that for cognitive benefits, the exercise should ideally be, you know, more than just a casual stroll.

Oh, much.

It suggests aiming for something more moderate, maybe at least three times a week. They also point to mentally stimulating activities, following a Mediterranean style diet specifically, and managing sleep disorders like sleep apnea and severe sleep deprivation as potentially protective factors.

It really underscores that a holistic approach to health, physical, mental, social, likely plays a crucial role in long-term brain health. So, okay, if prevention is about mitigating risk. What about when someone has already been diagnosed with Alzheimer's or another form of dementia? What are the current approaches to treatment?

Right. Well, it's really essential to be clear here. At present, there is no cure for Alzheimer's disease.

No cure yet?

No. The primary focus of treatment currently is to help individuals maintain their cognitive and physical functions for as long as possible. The information sheet mentions that researchers are actively exploring various medications.

Okay.

Some medications can provide temporary improvement in memory and other cognitive functions, particularly in the early to middle stages of the disease.

Temporary improvement.

Yes, temporary. It's important to understand that these medications don't halt or reverse the underlying progression of Alzheimer's itself. They manage symptoms for a time.

Okay. What about for other types of dementia? Is the treatment strategy similar?

Generally, yes. For dementia broadly, there are certain medications that can help manage symptoms, but again, these are not cures and their effective can vary quite a bit depending on the specific type of dementia and the individual person.

Right?

The medical document provides a more detailed overview of the overall goals of therapy. These include trying to slow down the disease's progression to optimize the person's abilities for longer.

Okay.

Managing both the cognitive symptoms like memory loss and the behavioral symptoms like agitation or anxiety

which can be very challenging for families.

Extremely challenging. Also reducing the risk of harm, minimizing any side effects for medic and crucially providing support to alleviate the burden on caregivers.

That caregiver aspect is huge. The medical document also mentions specific classes of medications. I think like uh choline eststerase inhibitors and NMDA receptor antagonists. Can you give us a general idea of how those work?

Certainly without getting too technical challenging galantamine.

Yeah.

They work by helping to increase the levels of acetylcholine in the brain.

Acetylcholine.

Yes. It's a cru chemical messenger involved in memory and learning by preventing its breakdown. These medications can sort of boost nerve cell communication. They're often prescribed for cognitive and functional symptoms in Alzheimer's and sometimes in other dementias like vascular louisibody and Parkinson's disease dementia.

Okay, so they boost brain chemical and the other type NMDA.

NMDA receptor antagonists. The main one is meantine. It works differently. It helps regulate the activity of another brain chemical called Glutamate. Too much glutamate can be harmful when nerve cells are damaged.

Oh, okay.

So, mmentine helps protect against that.

It's often used in moderate to severe stages of Alzheimer's. Sometimes together with a colonest race inhibitor.

So, it sounds like the current medications are really aimed at managing the symptoms and maybe slowing the decline a bit, but not stopping or reversing the actual disease process itself.

That's a fair summary of where things stand currently. Yes.

And the medical review also really emphasizes the critical role of non-farmacological treatments, doesn't it? Things besides medication.

Absolutely. It stresses that things like ongoing physical exercise, engaging in cognitively stimulating activities, and maintaining social connections are considered beneficial for most individuals living with dementia.

So, those lifestyle things are important after diagnosis, too.

Very much so.

Yeah.

There's also something called cognitive stimulation therapy or CST. It's a specific structured therapy involving group activities and it has shown to be help for people with mild to moderate dementia

CST. Okay.

And interestingly for front temporal dementia, the review notes that non-farmacological approaches often form the primary strategy for management as medications are less effective there.

The medical document also strongly underscores the importance of early advanced care planning.

Right. Things like power of attorney.

Exactly. Establishing legal documents like medical and financial power of attorney while the person can still participate in those decisions. It's really crucial. It's clear that providing support for caregivers is also just a vital aspect of managing dementia effectively.

Yes, absolutely. Our sources emphasize that Alzheimer's and other dementias has such a significant impact on the entire family. They're often referred to as family diseases.

That's a powerful description.

It is. And providing comprehensive support for caregivers, respit care, education, support groups is absolutely essential. Furthermore, encouraging the person with dementia to be involved in their care decisions is as much as they are able.

Maintaining their dignity and autonomy.

Precisely and addressing any fears they may have about abandonment or embarrassment were also really crucial aspects of compassionate care.

This has been a really comprehensive overview. Thinking about listeners who might be concerned, what are some key warning signs that should prompt someone to seek professional medical advice? When should they talk to a doctor?

Good question. Both information sheets provide clear guidance on this.

If you or someone you know is experiencing memory loss that is noticeably interfering with daily activities, not just occasional forgetting, but real difficulty. If the frequency of memory lapses seems to be increasing, if there's a growing tendency to forget recent events or the names of familiar people consistently,

getting lost even in familiar surroundings or really losing track of time regularly,

these are all signs that it's definitely advisable to consult with a healthcare professional. Don't just dismiss it.

Get it checked out. Okay. And for those who want to delve deeper or find support resources. Are there specific organizations you would recommend based on our sources?

Yes, absolutely. Both of our information sources specifically point to the Alzheimer Society of Canada.

Alzheimer Society Canada.

Yes. Their website is www.alzheimer.ca. That's alzheimer.caca. They offer a wealth of information, support services, and resources for individuals living with Alzheimer's or other dementias as well as for their families and caregivers. A really valuable resource.

Excellent. So, to kind of bring this deep dive toward a close. What are the most important key takeaways that we should really keep in mind from all this information?

Okay, I think firstly Alzheimer's disease is a specific and progressive form of dementia. It's not normal aging.

Key distinction.

Yes, dementia itself is that broader syndrome, a decline in cognitive functions with a variety of underlying causes.

We've learned there are identifiable risk factors and importantly some of these can be modified through cont ious lifestyle choices.

That 40% figure really sticks out.

It does. Current treatments, we need to remember, primarily focus on managing symptoms and supporting function rather than offering a cure at this point. And seeking timely professional evaluation and support is crucial for both diagnosis and ongoing care for the person and their family.

It's so important to remember that understanding these conditions requires us to look beyond just simple forgetfulness and recognize the more significant and persistent changes in cognitive abilities, right?

Exactly. And maybe considering our growing understanding of those modifiable risk factors, it prompts a really interesting question for you, the listener, to think about. What proactive steps based on what we've discussed today, diet, exercise, social connection, brain activity, managing health conditions? What steps might have the most significant positive impact on your long-term brain health?

H something to reflect on.

Definitely, we encourage you to think about the information we've covered and perhaps explore those resources we mentioned like the Alzheimer's Society website for your own further learning and reflection.

Ultimately, gaining knowledge is a powerful tool, isn't it? And we really hope this deep dive has provided you with a clearer and perhaps more empowering understanding of Alzheimer's disease and dementia.

ترانسکریپت مبحث مشکلات خواب یا insomnia
Welcome to the deep dive. Especially for all of you getting ready for your Canadian pharmacy PBC exams, we're really zeroing in on a key topic today. Insomnia.

That's right. We've gone through the Canadian Pharmacist Association's CTC reference pretty thoroughly.

Yeah, we've pulled out the essential details, uh, the therapeutic choices, medication algorithms, those important tables, and the tips you absolutely need.

Our goal here is to give you a concise, easy to follow summary. We want you to feel confident you have missed anything crucial for the exam and you know for your future practice too.

Exactly. Clarity, accuracy, practical insights. That's what we're aiming for. And this deep dive is brought to you by Pharma Board Group. All based on that CTC reference material.

Absolutely.

Yeah.

We know you need the core stuff on insomnia management efficiently. So, we're hitting those definitions, the treatment options, how those medication decisions get made,

and highlighting those key tips relevant for the PBC. Think of this as your go-to for getting this topic straight.

Okay, let's jump in the definition first,

right? So, the sources define insomnia as fundamentally dissatisfaction with sleep quality or quantity,

but it's more than just, you know, tossing and turning once in a while.

Exactly. To really meet the criteria, you need at least one specific issue. Difficulty falling asleep, trouble staying asleep, or waking up way too early and not being able to get back to sleep.

And crucially, this has to happen at least three nights a week for at least 3 months.

Yes, that 3mon duration. is key. Plus, it needs to cause real distress or impair your daily life work, social stuff, concentration.

That 3-month mark, yeah, that's critical for you to know for the PBC. It's the line between insomnia disorder and what's called short-term insomnia disorder,

which used to be called acute insomnia, right? For less than 3 months.

Exactly. Knowing that difference helps determine chronicity and guides the treatment path, which is definitely exam territory.

And another important point, insomnia isn't always like the main problem itself.

H, good point.

The sources stress. It can be a symptom of something else, maybe a risk factor for other issues or yes, a standalone disorder.

And it very often exists alongside other conditions, other sleep disorders definitely, but also psychiatric things like depression, anxiety,

medical problems, chronic pain, sleep apnea, you name it.

So identifying these coorbidities, these coexisting conditions is absolutely vital. You can't treat the insomnia effectively in isolation.

And as future pharmacists, you need to think how these co-orbidities might sway your medication choices. Right.

Definitely. And because it's so often tangled up with other factors, behavioral interventions are really the foundation. That's the cornerstone of treatment.

Even if you end up needing medication,

even then, CBTI, cognitive behavioral therapy for insomnia, is the big one highlighted. It's a multicomponent treatment tackling those behaviors and thought patterns. That'll be key for your PBC understanding.

Makes sense. But it gets trickier if there are significant coorbidities involved.

Oh, for sure. Sure. Table three in the reference gives examples psychiatric, medical, even medication related causes,

right? And in those cases, maybe you need a combo of meds and behavioral therapy or perhaps even a referral to a sleep clinic.

Knowing when to escalate, when to refer, that's part of the pharmacist role, too.

So, what are we actually trying to achieve with treatment? What are the goals?

The number one goal, and remember this with the exam, is improving daytime function.

Ah, interesting. Not just fixing the night. Well, patients often focus on the night, but we need to assess how their poor sleep is hitting their alertness, their mood, their ability to get through the day.

And think about medication safety, too.

If a patient's concentration is impaired, that's a huge risk factor, something we as pharmacists really need to consider.

Exactly. We also want to reduce that daytime impairment, the fatigue, the low mood, the brain fog. The aim is restorative sleep.

Sleep that actually makes you feel rested and resilient even if there are you know disruptions like noise or stress

right building that sleep resilience and for chronic cases potentiating those behavioral interventions making them work better

okay let's shift to investigations how do we assess someone with insomnia

the sources describe it as a layered approach you look at predisposing factors

like maybe someone's naturally prone to anxiety

precisely then precipitating factors what actually triggered the insomnia a stressful event maybe

and finally perpetuating factors those habits or belief that keep the insomnia going even after the trigger is gone.

Understanding those layers helps build a full picture for the management plan

and a thorough sleep history is non-negotiable here. Table one details this.

Yeah, you need the when, bedtime, wake time, time trying to sleep, the how much time to fall asleep, number of awakenings, total sleep time,

and the how good, the qualitative side, how satisfied are you, feel rested.

The history also digs into behaviors and environment. Using the bed for watching TV, groom temperature, partner disturbance, pets,

right? All those details and symptoms of other sleep disorders are crucial, too. Snoring, leg movements,

definitely need to screen for apnea or restless legs. And then daytime factors, naps, exercise, caffeine, alcohol, nicotine intake, it's a tall part of the puzzle.

What about sleep diaries? Table 2 mentions those.

Yeah, sleepwake diaries can be really useful. Tracking patterns over a week or two gives objective data. Good for monitoring progress during CBT. eye too.

But there's a caution, right?

There is. For some people, focusing too much on tracking sleep can actually ramp up the anxiety about it. So, use judiciously. Focus on daytime function

and questionnaires like the insomnia severity index.

Helpful standard measures. Yes. But the sources say use them with coorbidity assessments, not just on their own.

Okay. And actigraphy, the risk device thing.

It can supplement diaries, measuring movement to estimate sleep. But remember, meds and other disorders can affect accuracy. Commercial ones are rough estimates needing clinical interpretation.

Got it. What about the full sleep study polymography?

Generally not for the initial routine check of simple insomnia.

But when would it be needed?

If you suspect other sleep disorders like apnea or periodic limb movements or if the insomnia is chronic and resistant to treatment or if you're considering long-term hypnotics

and home polyenography is an option for uncomplicated sleep apnea. I believe

that's right. So the big takeaway for assessment screen for other sleep disorders. Check medications thoroughly. Table three lists meds that can interfere and always consider coorbidities.

Use those screening tools mentioned in table four like stopbang for apnea or PHQ9 for depression to guide you. You need to be familiar with those.

Absolutely. Proper assessment sets the stage for the right treatment.

All right, perfect. We've defined it, discussed assessment. Let's move into therapeutic choices. Figure one gives that management algorithm.

And we start with non-farmacologic options. As we said, good sleep hygiene detailed in table 5 is fundamental. It's the base layer,

but often not enough on its own for diagnosed insomnia disorder. Right.

Correct. It's always part of the first line treatment, which is CBTI.

Cognitive behavioral therapy for insomnia. Multicomponent, usually up to eight sessions, individual or group. Tables six and seven break it down.

And it's effective not just for primary insomnia, but also when it's alongside other medical or psychological issues. Often improves both.

How quickly can you see results?

Often within three to four sessions.

which is encouraging. Addressing those unhelpful beliefs about sleep upfront is important. The DBA scale can help identify those.

And even primary care docs can use modified versions, it seems.

Yes, it's becoming more accessible, but there are barriers realistically

like what?

Lack of trained specialists. Costs can be an issue. Sometimes patient acceptance or sticking with it is tough.

But there are alternatives emerging. Digital options.

Definitely digital CBTI is growing. Some are pricey like Haleo or Sleepy. Others more moderate like CBT for insomnia go to sleep. And some are even free like CBTI coach or my sleep well.

Good to know those options exist. There are also shorter versions, self-help materials, internet delivered CBT,

which can be just as effective and much more accessible for many people. Knowing these options is great for your future recommendations.

Still, CBTI doesn't work for everyone.

No, about one in four or five don't respond fully and up to 30% might drop out.

So having other non-drud strategies good, too,

like Exercise,

aerobic exercise can promote deeper sleep. Yeah, mindfulness meditation, bright light therapy show modest benefits.

Weighted blankets, I saw that mentioned.

1 RCT showed a significant reduction in severity, which is interesting. Acupuncture evidence is currently low quality

and things like music, foot baths,

very low quality evidence, but hey, low risk, too. Might help some individuals.

Let's quickly run through those core sleep hygiene guidelines from table 5. These are basics you'll be telling patients. all the time.

Okay. Regular sleepwake schedule, even weekends. Restrict time in bed to actual sleep time. Avoid long naps.

Regular exercise, but watch the timing. Maybe not too close to bed. Avoid caffeine late in the day. Limit alcohol. No nicotine or drugs.

Windown routine before bed. Warm bath. Maybe keep the bedroom cool like 1620° C. Dark. Quiet.

Avoid big late meals, though. A light carb snack might be okay. Turn the clock away. Stop watching it.

Bedroom for Sleep and intimacy only. If you're awake for say 15 minutes, get out of bed, do something quiet, then try again when sleepy.

Okay. And the five components of CBTI itself from table six.

Right. One, stimulus control. Strengthen bed sleep connection. Go to bed only when sleepy. Get out if not asleep in 15 minutes. Use bedroom only for sleep intimacy. Regular wake time.

Sleep hygiene. What we just covered.

Three. Sleep restriction. Initially limit time in bed to average sleep time maybe 6 7 hours. Gradually increase If sleep efficiency improves, best done with guidance.

Four, relaxation techniques, meditation, progressive muscle relaxation, things to calm hyperarousal.

And five, cognitive therapy, targeting and changing those dysfunctional beliefs about sleep. Table 7 gets into those,

right? Table 7 talks about realistic expectations. Bad nights happen. Don't blame everything on poor sleep.

Avoid catastrophizing. Don't make sleep the absolute center of your life. Develop tolerance for imperfect sleep.

Maybe adjust your schedule a bit, but Don't cancel everything after one bad night.

Exactly. Shifting those thought patterns is huge.

Okay. Really good overview of the non-drug side. Now, pharmacologic choices. What needs to happen before considering drugs?

Several prerequisites and these should be documented. Sleep education, discussing CBTI, ruling out other sleep disorders, maybe with studies, and optimizing treatment for any coorbidities.

Got it. And how do drugs compare to CBTI short-term?

Comparable efficacious during that acute phase actually. And sometimes combining meds and CBTI works well.

But there are significant downsides to many approved meds. Side effects, long-term risks. Table 10 covers this later.

Yes, definitely. And a key point, trial populations often don't have major coorbidities, but in reality, most insomnia patients do, maybe 75%.

So using sedating meds off label for comorbid insomnia might make sense if it treats the other condition too.

It can be a rational approach. Yes. Like a sedating anti-depressant if they also have depression.

The guiding principle for any Hypnotic

lowest effective dose shortest possible duration frequent follow-up especially early on say every 3 6 weeks limiting quantities initially maybe 30 60 days supply

and if things don't improve in say 2 to 6 weeks

re-evaluate everything diagnosis coorbidities consider a sleep specialist referral long-term sedative use happens but should be the exception

needs a clear rationale ongoing assessment

absolutely though some newer agents like isoplone zulpedum lumbberant have shown safety up to 12 months Okay, let's talk specific classes. Benzoazipines,

they all have seditive properties but differ in potency, pharmacocinetics. But the risks are significant. Delarium, falls, accidents, respiratory depression, cognitive issues, abuse, dependence, withdrawal. Big concerns in the elderly or medically ill.

What about links to mortality or dementia?

Older studies suggested it, but newer data isn't so clear. Still, short duration, intermittent use is generally safer.

Which ones are indicated for insomnia in Canada.

Flores pam, nitrozipam,am,am,am,am,am,am,am,am,am,amausipam, triazelam, tmasipam is often suitable. Halflife covers sleep without too much hangover.

Fluorizipam and nitresam

generally not recommended. Long half- lives they accumulate more next day effects, cognitive issues in older adults.

And triazel

also not recommended. Higher risk of abuse, dependence, rebound insomnia can cause confusion, agitation, amnesia at higher doses.

So benzo are really for short-term acute situations or maybe intermittent use

pretty much long-term only for severe cases failing other things with clear functional benefit shown and even then studies only go up to about 24 weeks

deeprescribing should be considered gradual taper

yes taper slowly over months explore lower doses but aggressive restriction can backfire sometimes a harm reduction approach for long-term users is needed

okay what about the Z drugs zopone isopacone zulpadm

benzoazopene receptor agonists they act on the same receptor but are more selective. Similar sleep effects, but potentially less impact on sleep structure. Fewer side effects like cognitive issues, dependence, tolerance, rebound,

less muscle relaxation too, don't worsen sleep apnea as much.

Generally, yes, they target different GABA alpha subtypes. Table 8 shows us, but the same advice applies. Lowest dose, shortest duration.

What about complex sleep behavior? Sleepwalking, sleep driving

rare, but reported maybe up to 3% with zoplonazm. Need to discuss this risk. Take it right before bed. Ensure a safe environment

and definitely no alcohol with them right now.

Absolutely not. Increases all adverse events including those behaviors. Critical counseling point.

Zopicone is common here in Canada. What about esopacone?

It's the S isomer. Similar but the slightly different receptor profile. Possibly more potent, quicker onset, longer duration, maybe fewer nextday effects than Zopacone.

Driving warnings.

Both need 12 hours before driving machinery, but Zopocone seems riskier for actual driving impairment.

A zoplone might have better efficacy. tolerability overall based on some reviews even for comorbid insomnia without much tolerance withdrawal reported

zopadm

more specific for the alpha 1 subtype shorter half-life 8 hours before driving it is a controlled substance unlike zopocon zoplone

and zavlon

also alpha 1 specific even shorter half-life not sold commercially now but can be compounded good for sleep onset issues minimal next day effects cable 8 summarizes those receptor affinities useful detail for the PBC

right what about other hypnotics doc spin

very low dose 3 to 6 milligram. It's a TCA, but at this dose, it's mainly a selective histamine H1 antagonist. Works on the histamine wake system, not GABA.

Indicated for sleep maintenance.

Yes, up to 3 months. Might be better for staying asleep than GABA drugs. No rebound dependence. Minimal next day effects.

None of the usual TCA side effects at this low dose.

Liberex, that's newer.

Adora dual orexin receptor antagonist. Reduces wakefulness to normalize sleepwake for sleep onset and maintenance

benefits.

No withdrawal rebound scene. Y up to 12 months. Somnulence is a side effect but minimal next day driving cognitive impact reported. Not controlled low abuse potential needs 7 hours before drive.

Floral hydrate barbiterates

definitely not recommended. Too toxic abuse potential saver options exist.

Okay. Now table 9 off label agents. When might these be used?

Often for coorbid insomnia as we touched on sedating anti-depressant for depression insomnia creatine for bipolar insomnia. Maybe gapentin for fibromyalgia insomnia.

So if it treats the coorbidity effectively.

That's often the rationale. Is opacone, ZulpaMem, Lmberrexant might also work well for comorbid insomnia even though approved for primary and remember sometimes approved agents are contraindicated in coorbidities like Zdrugs benzo and alcohol use disorder.

Using off label requires careful practice though

absolutely education, consent, monitoring, documentation, crucial steps.

Trazodone is used a lot off label just for insomnia. Right.

It is very widespread. But the evidence for lowdosese trazadone 2500 mg without coorbidities is actually pretty limited. Few small lowquality studies. Table 9 details these off label options and considerations. Important to understand for practice.

What about natural supplements and OTCs? People use them a lot.

Very common. Yeah. A Canadian study found over 14% use them.

Melatonin

has the most evidence but the overall effect size is small.

Valyan elryptophen.

Inconsistent results but might help some people critically. The compendium of therapeutics for minor ailments has more detail on these.

What about things like Tylenol, PM, Benadryil, Gravel, Nyquil? They contain antihistamines like diffenhydramine

generally discourage those especially for older adults. Increased risk of cognitive impairment, hangover, dizziness, antiolinergic delirium falls. Safer options are usually better.

Cannabis

insufficient evidence for routine use. Effects are complex and unclear. Maybe consider it only in resistant comorbid cases where it might help the other condition like pain or anxiety after other treatments. fail

THC visa CBD

THC is more sedating but psychoactive CBD dominant is usually preferred initially counsel patients on the limited evidence and risks

okay let's touch on special populations children

non-farmacologic first line always under six may be graded extinction medication isn't really evidence-based more empirical clinical experience treating coorbidities

melatonin

possibly 0.51 milligram initial dose met analyses show it can help shortterm for sleep onset especially in AD HDASD kids long-term data up to 7 years seems okay

other natural products antihistamines

limited evidence for things like elryptophan OTC antihistamines definite recommended tolerance sedation cognitive issues paradoxical reaction

prescription meds

judiciously for coorbidities like clonodine sometimes for ADHD insomnia zd drugs ineffective in kids benzo tca is generally unfavorable riskbenefit

what about the elderly

big risk of polyarm pharmacy interactions side effects like cognitive impairment falls so c PTI is even more crucial first line

safer med options.

Lower dose doxins 6 milligram for maintenance melatonin for onset. Lumbrex showed favorable safety efficacy over 6 months.

Benzo Z drugs

generally avoid due to fall confusion risk. If needed maybe shorter acting ones like Zulpadm or compounded xylopon lowd dose esopacone 2 milligram showed some short-term efficacy with low fall risk.

Lowdos trazadona mortazipene commonly used off label.

Yes. With little evidence specifically for insomnia. and elderly reserve for comorbid depression, anxiety or resistant cases. Conflicting evidence on false fractures.

What about stopping long-term hypnotics in stable elderly patients?

Discuss deprescribing. Yes, but way risks benefits.

Rigidly stopping a low dose that's working might cause harm. And remember, other meds cause false too.

Insomnia and pregnancy very common, right?

Extremely common. Worsens with pregnancy hormones, discomfort, bladder pressure, postpartum too, obviously. Anxiety plays a role. Sleep apnea less can work. Research is limited.

Yes. On impact and interventions, but it definitely impairs quality of life. Mild, moderate cases respond well to CBT behavioral techniques.

Severe cases needing meds.

Careful risk benefit assessment needed for mother and fetus. Intermittent lowest effective dose with behavioral support.

Which meds might be reasonable?

Zopacone, esopacone, trazadone possibly justified. Avoid benzo's first trimester cleft risk neonatal withdrawal near term.

Doxipen anti-depressants.

Docipen not terodogenic but not studied. Anti-depressants generally low risk though small chance of newborn respiratory issues often confounded by the mood disorder itself.

Zulpadm lexin melatonin OTC's

zulpadm not recommended higher risk of preterm birth SGA c-section. Lemuraxin melatonin elryptophan dyen hydramine generally not recommended due to unknown safety or theoretical risks

and breastfeeding.

If meds are essential intermittent lowd dose short acting benzo like tamazipam or zd drugs seem relatively safe with monitoring. Chronic exposure effects unknown.

Other hypnotics

safety mostly unknown. Tresidone transfers in low amounts likely okay for infants 2 months if mom's dose is 100 milligrams. Doc's penipin hydramine not recommended adverse effects reported in infants. Always check specialized references. Non-drug first.

Great summary. Let's wrap up with some key therapeutic tips.

Okay. Rule out sleep apnnea if indicated. Screen for depression, anxiety, apnea, chronic pain initially.

Educate on Sleep hygiene. Set realistic goals. Focus on minimizing daytime impairment. A chronic poor sleeper won't become perfect overnight.

Remember, behavioral therapy takes time. 3 4 weeks maybe. Drugs might offer faster relief initially.

Daytime impairment severity guides the approach.

Yeah. Acute change might warrant short-term hypnotics. Mild chronic, usually behavioral first, like sleep restriction.

Theory versus practice with hypnotics can differ.

It can.

Yeah.

Long-term use is needed sometimes for function. Don't dismiss it entirely, but weigh risks benefits. Reluct might lead to suffering or unmonitored self-medication.

Warn about mixing with other CNS depressants, especially alcohol.

Absolutely critical. Never with alcohol.

Follow driving time frames initially, but remember, sleep deprivation also impairs driving.

Habituation to driving effects

can happen with regular use. Off label agents, less tested might be worse. Use clinical judgment. Consider reporting requirements for commercial drivers. Balance side effects with function.

Tapering off.

Plan it for a low stress time. Slow taper helps. If complete withdrawal isn't feasible, lowering dose frequency is still beneficial. Avoid rigid discontinuation dogma.

Insomnia is linked to psychiatric conditions.

Often a symptom, coorbidity, or even precedes things like depression, anxiety, chronic poor sleep raises mood disorder risk. Monitor for mood issues. Treat them appropriately, maybe before focusing solely on sleep. And keep screening for other coorbidities throughout treatment, especially if response is poor.

Perfect. And finally, table 10 gives the details on Health Canada approved meds. Tamezipam, opacone, zulpadum, zopocone, liberant, lowd dose, doxen,

dosage, side effects, interactions, warnings, especially for elderly, respiratory issues, OSA, rebound, driving, complex behaviors, it's all there.

And table four covers the non-prescription ones. Denin, hydramine, melatonin, elptophan, valyan. Similar info, plus notes on limited evidence, anticolinergic effects, pregnancy, breastfeeding cautions.

Knowing those tables inside out, out is really crucial for the PBC.

Okay, so to recap the absolute mustnoss for you PBC candidates, the definition of insomnia, that layered assessment approach, history, diaries, coorbidities, non-farmacologic treatments first, CBTI, sleep hygiene, then the pharmacologic options, benzo, Zdrugs, others knowing indications, side effects, special populations, and those practical therapeutic tips.

Understanding all this is vital for the exam obviously, but it's also the foundation for providing really good patient care later on. This deep dive gives you that overview. But definitely keep exploring the CTC referencing guidelines.

Absolutely. Now, let's test your recall with a quick question. Which of the following is generally considered the first line non-farmacologic treatment for chronic insomnia? Is it A sleep hygiene alone? B stimulus control therapy, C cognitive behavioral therapy for insomnia, CBTI, or D melatonin supplementation.

Think about the comprehensiveness of the approaches we discussed. And remember, if you have more questions or need resources, Pharma board group is there to help.

And our final thought, effectively managing insomnia makes a huge difference to a patient's life. Your role as pharmacists in providing evidence-based, patient focused care here is incredibly important. Thanks for joining us on this deep dive.

افسردگی
Welcome to this deep dive from the Pharma Board Group. Uh it's all based on the CTC reference material. And today we're really zeroing in on something critical for your Canadian pharmacy PEBC success. Anti-depressants.

That's right.

Think of this as your um streamlined guide. We're pulling out the absolute must know therapeutic choices, medication algorithms, key info from the tables, and well, essential tips.

All drawn from the comparative drug chart on anti-depressants that via vigilance sante and pharma board and also a really comprehensive document just called depression.

Exactly. Our mission here is pretty simple. Give you that crucial info uh clearly, concisely.

Yeah.

Boost your confidence for the exams. Make sure nothing vital gets missed. Let's unpack this.

Yeah, absolutely. We know you're juggling a ton of information. So, we're aiming to cut through some of the noise, bring you clarity, accuracy,

practical insights, too, right? For the PBC and beyond.

Exactly. Insights you can use for the exam and, you know, build a solid foundation for your practice later on. Okay, so before we jump straight into the drugs, it's really important to remember those first steps, the assessment phase.

They're crucial.

The sources really stress how vital a thorough assessment is. They mentioned screening tools like the PHQ2, those first two questions from the PHQ9,

right? A quick screen just to see who might need a well a closer look.

And then for that deeper evaluation,

yeah, for really understanding the severity and impact, you've got tools like the full PHQ9, the QIS SR16, HAMD7, and the Sheihan disability scale. They help paint a picture of how depression is affecting someone's life.

Makes sense.

And you know, it's vital to differentiate depression from something like bipolar disorder, those up phases, mania or hypomomania, right?

The mood disorder questionnaire, the MDQ, is designed specifically for that. We need to rule that out or identify it.

And for pregnancy and postpartum,

ah yes, the Edinburghough Postnatal Depression Scale or EPDS, that's a key tool for that specific population.

Definitely. And it's Not just about spotting depression itself. Assessing suicide risk is well it's non-negotiable.

Absolutely critical.

And looking at coorbidities too, right? Like anxiety, sleep problems, maybe cognitive issues.

Yes, exactly. Things like the insomnia severity index, sleep diaries, the Hamilton anxiety scale, even the Folstein test for cognition. They all add important pieces to the puzzle.

So getting that whole picture,

that's the goal, a comprehensive view. Then when we think about treatment, remember the DSM5R classifies different depressive disorders. We're focusing mainly on major depressive disorder MDD and persistent depressive disorder uh what used to be called distia.

Okay, let's unpack the difference there. MDD versus persistent depressive disorder. What are the key distinctions for the PBC?

Good question. So, table one in the depression document lays out the MDD criteria clearly. Basically, you need five or more specific symptoms in a two-eek period, right? And one of those must be either depressed mood or um Significant loss of interest or pleasure. Anadonia.

Got it. And persistent depressive disorder.

That one's more chronic. Think depressed mood lasting at least 2 years in adults. The symptom list is similar, but you only need two or more symptoms.

Like changes in appetite, sleep, low energy.

Exactly. Low self-esteem, trouble concentrating, feeling hopeless, those sorts of things. The key difference really is the duration. Even if the symptoms sometimes feel less intense daytoday than in a major depressive episode,

right? Chronicity is key. Important for thinking. a long-term management.

Precisely.

So once we have a diagnosis, what are the therapy goals? What are we aiming for?

Well, the main goals and these are always set with the patient are achieving remission, getting back to their usual self essentially.

Okay.

Also treating any other symptoms like anxiety or sleep issues, preventing suicide, restoring their functioning in daily life, and crucially preventing recurrence. Those apply to both acute and maintenance phases.

While we're focusing on meds today, we shouldn't forget non-farmacologic options.

No, absolutely not. Especially for mild to moderate depression, they're very important

like psychotherapy.

Yes. Things like CBT, cognitive behavioral therapy, behavioral activation, interpersonal therapy, often first line for less severe cases. And there are tech options, too, like web-based CBT.

That's useful.

And psycho education is key, too. Just explaining the illness, the treatment, stressing adherence, managing expectations about timelines, it really helps.

Lifestyle stuff, too. exercise, diet,

definitely exercise, yoga, maybe dietary changes, even light therapy for seasonal and sometimes non-seasonal depression. They can all play a role. But yeah, for this deep dive, we're honing in on the pharmacologic side.

Okay, let's dive in then. Pharmacologic choices.

What are the general principles we need to nail down for the PBC?

All right, figure one in the depression source gives a good visual algorithm. First point, the recommendations are generally the same for MDD and persistent depressive disorder.

Okay, that's Simplifies things a bit.

It does. And table 3 is super important. The CANMAC classification. It groups anti-depressants into first, second, and third line agents.

Can you give some examples?

Sure. First line includes many you'll know. Bropion, citoprellopram, fluoxitine, peroxitine, certuline, venlaxine, disbenlax, vioitine,

right? The common ones.

Second line might be things like levasipopran, mocklobomide, kishiopene, the atypical antiscychotic. We'll discuss trazadone. and the TCAs the tricyclic

and third line

generally reserved for the mais like phenoline trrenypermine more specialized use knowing this hierarchy helps guide choices

okay that's a great framework how about starting and adjusting doses

the general idea is to get to a minimum therapeutic dose pretty quickly ideally within the first two weeks

then you adjust over the next say four to six weeks watching response and side effects closely

and managing those side effects

vitally important you need to tell patients upfront what to expect. Look at table 4 for common ones. Reassure them that many side effects lessen within about 2 weeks.

But what if they don't or they're just too much?

Good point. If side effects are really intolerable even after trying dose adjustments, then switching might be needed. Maybe between weeks three and eight. Sometimes switching within the same class is enough.

Makes sense. Now, the source mentioned a big comparison study, a network meta analysis.

Ah, yes, that was interesting. It looked at both effectiveness and tolerability. What were the key findings?

Well, it suggests that agents like amitryptaline, acetylopram, erbotazipene, peroxitine, venlaxine, and vortioitine might be uh a bit more effective overall. Agamelatine too, but it's not available in Canada.

Okay, effectiveness. What about tolerability? Who came out better there?

On the tolerability side, the standouts were agamelatine again, esatalopram, fluoxitine, certuline, and vioitine.

So looking at both acetatelopram and vioitine, seem to hit a sweet spot

potentially. Yes. They seem to offer a good balance of being effective and reasonably well tolerated for many patients based on that analysis. Worth keeping in mind.

Definitely. Now, a really critical point, the potential risk of increased suicidal thinking or behavior,

especially in younger people.

Yes, this is a very serious consideration. It's complex. Some studies suggest SSRIs might reduce suicide risk in older adults, but regulatory agencies have issued warnings about a possible increased risk. particularly in children and young adults, especially early in treatment or when changing doses.

So, close monitoring is essential.

Absolutely essential.

You have to watch carefully for any emergence or worsening of suicidal thoughts or behaviors, particularly when starting or adjusting doses in younger individuals. It's a risk that has to be weighed against the significant risk of untreated depression itself.

Okay, really crucial point. Let's move into the specific classes. SSRI's first Selective serotonin reuptake inhibitors often first choice you said

that's right they're usually the go-to first choice why generally good tolerability pretty easy dosing usually once a day and you know cost is often lower than some newer drugs

which ones are available here in Canada

you need to know citilopram escalopreg fluoxitine fluoxamin peroxitine and certillene

okay how do they compare to older drugs like tcas

efficacy wise they're generally considered comparable to the tcas but the side effect profile is quite different

what kind of side effects are common with SSRIs.

You often see GI issues like nausea, maybe diarrhea, CNS effects like anxiety, sometimes insomnia or maybe feeling a bit jittery initially. And uh sexual dysfunction is a big one,

right? And what about that GI bleeding risk?

Yes, that's important. There's a potential increased risk, especially if patients are also taking NSAIS or if they have a history of GI bleeds. Something to screen for.

And the sexual dysfunction that can be a real problem. for adherence, can it?

It really can. And unlike some other side effects that might fade, sexual issues, lower libido, difficulty with orgasm, erectile dysfunction can unfortunately persist for some people throughout treatment.

So if that's a major concern,

then you might lean towards non SSRI options that have a lower risk profile for that specific side effect. Think bipen, mtazipene, mockabomide, perhaps vezadone or vioitine.

Good alternatives to keep in mind. Anything else specific about the SSRIs you mentioned? as cytoalopram earlier,

right? Acetyocram is similar to citylopram, its parent drug, but some data suggests it might have potentially superior efficacy in some comparison

and discontinuation effects stopping suddenly.

Big issue. Most SSRIs except fuoxitine because it has such a long halflife can cause discontinuation symptoms if stopped abruptly.

Fluxine kind of tapers itself.

Exactly. But for the others, like peroxitine especially, stopping suddenly can lead to dizziness, nausea, anxiety, flu-l like feelings. So gradual tapering and monitoring are key when stopping.

Okay, got it. Let's move to the SNRI's serotonin norepinephrine reuptake inhibitors. Venlaxine is a key one here.

Definitely venifaxine primarily hits serotonin at lower doses, but as you increase the dose, say above 150 milligrams a day typically, you get significant norepinephrine reuptake inhibition too, dual action.

Does that make it more effective?

Some studies mainly comparing it to fluoxitine suggest potentially higher remission rates, but it's not universally accepted as superior to all SSRIs.

Any specific side effects to watch for with vinax vaccine?

The main one to be aware of is a potential dose related increase in blood pressure. It's not super common, but more likely at doses over 225 milligrams. So monitoring blood pressure, especially at higher doses, is generally recommended.

Okay. What about other SNRIs? Does Venlaxine?

That's the active metabolite of Venlaxine. It might have slightly fewer drug interactions because of metabolism differences. Efficacy is generally seen as similar and it has shown some use specifically in perry and post-menopausal women with depression.

Common side effects

things like insomnia, maybe drowsiness, dizziness, nausea are pretty common.

And deloxitine.

Delloxitine hits both serotonin and norepinephrine right from the starting dose, usually 60 milligrams daily. It also has indications for things like neuropathic pain and fibromyalgia.

Right. Useful if those conditions coexist.

Exactly. A key point for Delloxitine is its metabolism. It uses the CY P1 A2 enzyme.

Ah, so smoking could affect it.

Precisely.

Smoking induces CYP1 YA which can lower delloxitine levels. You might need dose adjustments in smokers.

Good clinical pearl. And Levlazoprin.

Levlasoprine is interesting because it has a higher selectivity for norepinephrine compared to serotonin reuptake. Common side effects include nausea, headache, dry mouth, sweating, constipation, dizziness.

Any cardiovascular effects?

Yes, it can potentially increase blood pressure and heart rate. So monitoring might be needed especially in patients with existing cardiovascular issues.

Okay, moving on to the dualaction anti-depressants category in our source. First up is bupropion. What's its deal?

Bupropion is quite different. It works mainly on norepinephrine and dopamine reuptake, not so much serotonin. It's a first-line agent for MDD and of course also used for smoking sessation.

What's the big warning with bupropion?

Seizure risk. It lowers the seizure threshold. And this effect is dose dependent. So it's contraindicated if someone has a seizure disorder or a history of anorexia or bulimia which also increase risk. Caution is needed with head trauma history too.

But on the plus side,

less GI upset and significantly less sexual dysfunction compared to SSRIs. That's a major advantage for some patients.

Okay. And the other one in this category,

mortazzipene.

Mertzipene works differently again. It enhances neurogeneric and serotonin activity but mainly through blocking certain receptors. Al adrenuric and some serotonin receptors.

What a effect profile.

Generally lower rates of GI and sexual side effects compared to SSRIs. However,

there's always a however.

Yeah, it's often associated with sedation especially at lower doses paradoxically and weight gain. Those can be significant drawbacks for some.

Right. Okay. Next category. Other serotonin modulators. Trazadone first. Often used for sleep. Right.

Exactly. It's a serotonin 2 receptor antagonist and weak reuptake inhibitor at anti-depressant doses. It's usually too sedating for daytime use for most people.

So lower doses at night.

Yes. Commonly used off label at lower doses, maybe 50, 100 milligrams as a sleep aid, often alongside another anti-depressant. An advantage is that tolerance to the sedative effect doesn't usually develop like it can with benzoazipines.

Okay. Vardioitine is next. We touched on its good balance earlier. What about its mechanism?

It's called multimodal. It inhibits the serotonin transporter like an SSRI, but also acts directly on several other serotonin receptors, antagonizing some, agonizing others.

Any unique benefits?

There's some interesting data suggesting it might improve cognitive function, like attention, processing speed in patients with MDD, which is a potential advantage.

Side effects,

mainly GI, nausea being the most common, but it often improves after the first week or so. Evidence suggests potentially lower rates of sexual dysfunction and sleep issues compared to typical SSRIs, but still needs monitoring.

And the last one here, Velozo. Plazadone combines SSRI activity with being a partial agonist at the 5HT1A receptor.

Anything special about taking it?

Yes, it needs to be taken with food for proper absorption. That's important counseling. And usually you start low and titrate up gradually to minimize GI side effects

which are

most common are nausea, diarrhea, headache. But like vioitine, it seems to have a lower frequency of sexual side effects compared to standard SSRIs.

Good to know. Okay, let's talk tricyclic antidepressants.

TCA case generally second line you said why

primarily because of tolerability and safety concerns they hit multiple receptors histamine acetylcholine alpha adinuric leading to more side effects like sedation dry mouth constipation dizziness and the big one is cardiotoxicity and overdose it can be lethal

the examples

amatipptalign nippalign desoperine clomoprein doxpin tremoprammin they vary a bit in their norepinephrine versus serotonin effects

any specific uses still Clomopramine is still often considered a good choice for OCD obsessivempulsive disorder due to its strong serotonin effects.

Right. And then monoamine oxidase inhibitors mais these sound serious.

They are the irreversible ones phenoline and tranylermen are generally third line used in specialized clinics.

Why the caution?

Big risk of interactions. The classic one is hypertensive crisis if combined with tyramine rich foods, aged cheeses, cured meats, certain beers. Also risk of serotonin syndrome with other serotoninergic drugs. Strict dietary and medication restrictions are vital.

So high-risisk profile

definitely. But there's also mlobamide.

How is that different?

It's a reversible and selective inhibitor of MAOA or RIMA. At standard doses, it generally doesn't need the strict dietary restrictions. It's better tolerated and can be a useful option sometimes, particularly if there's a lot of anxiety alongside the depression.

Okay. What about using atypical antiscychotics for depression?

Yeah, they're mainly used as augment ation meaning adding them on when an anti-depressant alone hasn't worked well enough.

Which ones?

Extended release quichipene is actually approved as monotherapy. Second line, the immediate release version is sometimes used but is more sedating. Then you have arapiprazole and brexiprazol approved specifically as add-ons to anti-depressants for inadequate response.

Any others used off label?

Alanzipene and respperadone are sometimes used off label as adjuncts too in treatment resistant situations.

How quickly should you see a response? If you add one,

generally if it's going to help, you should see some improvement within about 2 weeks.

Okay. And lastly, the NMDA receptor antagonist. This is newer territory, right?

Relatively, yes. Esetamine, the intraasal spray, is approved in Canada for treatment resistant depression, but only alongside an oral SSRI or SNRI.

Any restrictions?

Oh, yes. It's under a controlled distribution program because of potential dissociation, sedation, and misuse potential. Needs to be administered in a certified setting. and ketamine itself. For ketamine,

foreign ketamine has shown rapid anti-depressant effects in studies. Canmat considers it a thirdline option for treatment resistant depression based on short-term data. Again, usually administered in specialized clinics due to monitoring needs.

Wow. Okay, that covers the main classes. Let's circle back briefly to adverse effects in general. Key takeaways for the PDC.

Table four in the source is your friend here. It lists common side effects and management strategies. Big picture. If side effects are severe, persistent, or just not tolerable, you need to think about reducing the dose or switching meds.

Common ones to expect across classes,

GI upset, activation or anxiety initially, sleepiness or trouble sleeping, weight changes, gain is common with some, loss with others initially, and sexual dysfunction. Know which drugs are more prone to which effects.

And serotonin syndrome,

yes, be aware of it. Rare but serious. Caused by too much serotonin, usually from combining multiple serotonin drugs. Know the symptoms like confusion, agitation, rapid heart rate, sweating, tremor, rigidity, and that management involves stopping the offending agents and providing supportive care.

Okay. What about stopping anti-depressants? Discontinuation syndrome.

Very important counseling point. Stopping abruptly or reducing the dose too quickly can cause this. It's common, especially with SSRIs, just because they're used so much, but can happen with most anti-depressants taken for say 6 weeks or more.

Which drugs are highest risk?

Those with shorter half- livives. Peroxitine and venaxine are classic Examples, fluoxitine with its long halflife is the least likely. Symptoms

can be varied. Dizziness, nausea, lethargy, headache, anxiety, irritability, insomnia, sometimes weird sensory stuff like brain zaps

can feel like the flu.

So, how to manage it?

Tapering. Gradually reduce the dose.

A common suggestion is maybe 25% reduction per week, but it needs to be individualized. Monitor for withdrawal symptoms and also for relapse of the depression itself.

Is it dangerous?

Generally, no. It's uncomfortable but not life-threatening. Usually resolves within say 3 weeks. Reassure patients about that. If symptoms are bad, you might need to restart the drug and taper much more slowly or sometimes use fluoxitine to help bridge the taper because of its long halflife.

Got it. Okay. Special populations, pregnancy, and breastfeeding. What are the key considerations?

It's always a risk benefit discussion. Weighing the risks of medication exposure against the risks of untreated maternal depression, which can also harm both mother and baby. So for pregnancy

psychotherapy is first line for mild moderate for moderate severe especially with prior history antid-depressants are often considered firstline treatment.

Which ones are preferred?

Often citellopram esopram and certuline are considered firstline due to having more reassuring safety data. Peroxitine has some concerns particularly regarding cardiac malf forations and fluoxitine's long halflife can be a consideration near delivery.

What to avoid?

Mis are generally avoided. Doc's been too

and postpartum especially with breastfeeding.

Postpartum blues are common and usually pass. For postpartum depression, psychotherapy again is a great first step. If meds are needed while breastfeeding, certuline alprag and citalopram are often preferred first-line choices because relatively low amounts get into breast milk.

Avoid docuin here too.

Yes, docin is generally not recommended during breastfeeding due to potential infant sedation. Always consult current guidelines for this area.

Absolutely. Now, the source has offered some great therapeuticips. tips. Can we highlight a few really key ones for PBC prep?

Definitely. One good tip, try to get really comfortable with maybe one or two agents from each major class. Know their dosing, side effects, interactions really well.

Makes sense. Avoid being overwhelmed.

Exactly. Always individualized treatment. Consider coorbidities. What symptoms are most bothersome for this patient?

And communicate well.

Crucial. Talk about side effects, interactions, discontinuation potential before they start. Provide that psycho education, what to expect, importance of adherence right at the beginning and reinforce it.

Combination therapy

often superior. Combining meds and psychotherapy like CBT or IP frequently gives better outcomes than either alone. Meds might work faster, but therapy can help reduce long-term relapse risk. Stress the importance of maintenance therapy.

What about things like drug level monitoring or genetic testing?

Generally, limited role in routine practice right now. Maybe in specific complex cases, but not standard first-line guidance. And if someone isn't responding,

review everything. Adherence, diagnosis correct, coorbidities addressed. After maybe two or three failed trials, or if psychosis or acute suicidality appears, definitely consider a psychiatric consult.

Then the taper again.

Yes, taper slowly when stopping. Especially peroxitine and venla vaccine. Think four or 6 weeks, maybe longer.

Great summary. And table six, the big drug table.

Invaluable resource. It has specifics on brand names, dosages, side effects. key interactions for pretty much all the anti-depressants we've discussed, plus antiscychotics used as adjuncts, MAOIs, even things like St. John's wart, your go-to for detailed drug info.

Speaking of which, natural health products. What's the quick takeaway?

St. John's wart has some evidence for mild moderate depression, but huge e potential for drug interactions. Check carefully. Sam has less robust evidence, generally well tolerated, but still carries a serotonin syndrome risk with other serotonergics.

Omega-3s, vitamin D, studied, but currently the evidence for benefit in depression is considered low quality, not primary treatments.